冬凌草单药及与化疗合用治疗食管癌205例

目的:观察冬凌草单药及与化疗合用治疗食管癌的临床疗效.方法:448例患者,均经病理细胞学和X线检查确诊为食管癌.其中早期癌76例,均采用冬凌草单药治疗.晚期癌372例,167例采用冬凌草单药治疗,205例采用冬凌草与化疗合用.结果:用冬凌草单药治疗早期食管癌患者3,5,10,13 a的生存率明显高于未治疗组(98.68% vs 51.52%,84.02% vs 28.62%,63.49% vs 11.45%,50.13% vs 8.59%;P<0.001).对于晚期食管癌,冬凌草联合化疗应用,其总有效率明显高于以PYM(BLM)为基础的单一化疗(66.82% vs 42.85%,P<0.01).冬凌草与化疗合用组与单一化疗对照组相比副作用基本相同,无明显差异(P>0.05).结论:对于早期食管癌患者,冬凌草能控制疾病发展延长生存时间;对于晚期食管癌患者,冬凌草能增强化疗的作用.     

湿润烧伤膏治疗褥疮26例的临床体会

目的:进一步观察湿润烧伤膏对治疗褥疮的疗效,寻找最理想的治疗方法。方法:通过对26 例不同原因所致褥疮的治疗,探索湿润烧伤膏对治疗褥疮病人最合理的用药方法,创面的变化及其愈合时间。结果:25例病人创面愈合,死亡1例。结论:湿润烧伤膏治疗褥疮方法简便,实用性强,疗效显著,值得各级医院推广。     

Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.

AIMS: To compare long-term (1 year) efficacy and safety of pioglitazone and gliclazide in patients with Type 2 diabetes. METHODS: This was a double-blind, multicentre, comparative, parallel group trial in 283 patients with Type 2 diabetes, who were randomized to receive 1-year treatment with pioglitazone 30-45 mg/day or gliclazide 80-320 mg/day. Drug dose was titrated on the basis of self-monitored blood glucose (SMBG) measurements and HbA1c values. The 1-year changes in HbA1c, fasting blood glucose (FBG), insulin, HOMA-S (HOmeostatic Model Assessment) and SMBG were compared. In a subgroup of patients (n = 10), systemic glucose production and utilization were determined by a combination of isotopic (deuterated glucose) and clamp techniques. RESULTS: In both groups, there were similar decreases in HbA1c (pioglitazone: -0.79%; gliclazide: -0.79%) and FBG (pioglitazone: -1.0 mmol/l; gliclazide: -0.7 mmol/l), whereas the slope of the reduction of fasting blood glucose was different between groups (P = 0.004). Insulin levels as well as insulin resistance assessed using HOMA-S decreased significantly only after pioglitazone treatment (-11.94 pmol/l and -1.03, respectively, both P = 0.002 vs. baseline). A significantly greater reduction in systemic glucose production was observed in the pioglitazone group (-2.48 micromol/kg/min, P = 0.042) than in the gliclazide group (-1.02 micromol/kg/min). A few, mild adverse events occurred in both groups. CONCLUSIONS: A comparable decrease in HbA1c and FBG was observed with pioglitazone and gliclazide. However, with pioglitazone there was a continuous decrease in FBG over 1 year, whereas gliclazide failed to maintain a similar trend. This favourable effect of pioglitazone was due to its insulin-sensitizing effect and ability to decrease systemic glucose production.     

对碘树脂型净水器产品结构与杀菌效果关系的探讨

近几年，我国对以碘树脂进行供水终端消毒作了一些研究，并有商品投放市场。这类产品杀菌效果除与所填充的碘树脂本身杀菌性能有关外，与产品结构也有很大关系。结构不同，水中微生物通过净水器的时间（即消毒作用时间）也将不同。经推导：消毒作用时间与碘树脂柱长度、直径以及碘树脂颗粒大小、填充数量、出水量大小等有关。因此，在产品结构设计时，可通过调整上述各参数，获得最佳杀菌效果。本文通过对这类产品结构与杀菌效果关系的探讨，为有关企业及部门合理设计产品内部结构提供了新思路。     

MEBO在血栓性外痔和陈旧性肛裂术后治疗中的疗效观察

目的：观察美宝湿润烧伤膏在血栓性外痔和陈旧性肛裂切除术后治疗中的疗效。方法：术毕用MEBO纱布条填塞伤口,术后24小时取出纱布条,以后用MEBO涂于伤口内,每日2次,直至痊愈。结果：48例患者无术后伤口疼痛、出血、感染及肛门狭窄。伤口愈合时间短,治愈率高。结论：美宝湿润烧伤膏是血栓性外痔、陈旧性肛裂切除术后良好的局部治疗药物。     

纤变灵对口腔粘膜下纤维化及血液流变学的影响

目的观察中药复方纤变灵治疗口腔粘膜下纤维化（OSF）的临床疗效及对血液流变学的影响。方法将确诊为OSF的66例患者随机分为两组，治疗组34例，对照组32例，分别给予纤变灵和维生素A、E口服，观察两种药物的临床疗效、血液流变学指标的变化。结果纤变灵治疗OSF临床疗效明显优于维生素A、E（p〈0.05）；全血粘度、血浆粘度、纤维蛋白原等血液流变学指标均有明显改善（p〈0．05或p〈0．01）。结论纤变灵治疗OSF安全有效，并能降低血液粘度、改善微循环。     

臭氧水对SARS病毒的灭活效果观察

为了观察电解法产生的臭氧水对SARS病毒的灭活效果,采用悬液灭活试验法进行了试验。结果,以臭氧含量为27.73mg/L,作用4min可完全灭活SARS病毒;以臭氧含量为17.82mg/L,作用4min和4.86mg/L作用10min,均可使SARS病毒的灭活率达100％。结论,电解法产生的臭氧水含臭氧量达到4.86mg/L以上,对悬液内SARS病毒具有很强的灭活效果。     

52例电烧伤的治疗分析

目的：总结电烧伤的治疗方法。方法：对52例资料齐全的电烧伤病人的治疗方法及疗效进行回顾性分析。结果：单纯电火花烧伤的治疗和一般烧伤相同，电击伤多为早期清创，植皮覆盖创面。结论：电烧伤创面根据情况可有多种治疗方法：包括单纯换药，湿润烧伤膏，中厚皮片移植，皮瓣移植等。     

Effectiveness of electroconvulsive therapy in community settings.

BACKGROUND: Clinical trials indicate that electroconvulsive therapy (ECT) is the most effective treatment for major depression, but its effectiveness in community settings has not been examined. METHODS: In a prospective, naturalistic study involving 347 patients at seven hospitals, clinical outcomes immediately after ECT and over a 24-week follow-up period were examined in relation to patient characteristics and treatment variables. RESULTS: The sites differed markedly in patient features and ECT administration but did not differ in clinical outcomes. In contrast to the 70%-90% remission rates expected with ECT, remission rates, depending on criteria, were 30.3%-46.7%. Longer episode duration, comorbid personality disorder, and schizoaffective disorder were associated with poorer outcome. Among remitters, the relapse rate during follow-up was 64.3%. Relapse was more frequent in patients with psychotic depression or comorbid Axis I or Axis II disorders. Only 23.4% of ECT nonremitters had sustained remission during follow-up. CONCLUSIONS: The remission rate with ECT in community settings is substantially less than that in clinical trials. Providers frequently end the ECT course with the view that patients have benefited fully, yet formal assessment shows significant residual symptoms. Patients who do not remit with ECT have a poor prognosis; this underscores the need to achieve maximal improvement with this modality.     

Oral mifepristone 600 mg and vaginal gemeprost for mid-trimester induction of abortion: An open multicenter study

This open multicenter study was performed in 20 hospital gynecological units in the UK. The effects of 600 mg oral mifepristone as pretreatment to vaginal prostaglandin induction of second second trimester abortion was studied in 267 women.

The primary efficacy variable was the abortion induction interval, defined as the time taken to expel the fetus from the time of administration of the first prostaglandin pessary. Induction was commenced 36 to 48 hours following mifepristone intake.

The mean abortion induction interval was 7 h. A total of 81.9% of women aborted within 12 h. There was a significant relationship between abortion induction interval and age of gestation, and a significant inverse relationship between abortion induction interval and parity.

Vomiting, pelvic pain, and nausea were the most frequently reported adverse events. Two patients required transfusion and one patient with a uterine scar from a previous cesarean section suffered a ruptured uterus and hysterotomy.